Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA), Synthesized Oligo (Primer), Reagents, Equipment), Type (Custom, Predesigned), Application (Therapeutic (Neurology, Rare), Research (PCR, Sequencing), Diagnostics) - Global Forecast to 2029

April 2024 | 432 pages | ID: O0BB67C32D0EN
MarketsandMarkets

Abstracts

The oligonucleotide synthesis market is projected to reach USD 19.7 billion by 2029 from USD 8.8 billion in 2024, at a CAGR of 17.5% during the forecast period. The synthesized oligonucleotide market is projected to reach USD 4.9 billion in 2029 from USD 2.2 billion in 2024, growing at a CAGR of 17.0% during the forecast period. The growth of this market is driven by several factors such as the increasing use of synthesized oligonucleotides such as primers and probes for various research and diagnostic applications. Technological advancements in the field of oligonucleotide synthesis further contribute to the growth of the market.

“The oligonucleotide synthesis market growth for synthesized oligonucleotides can be attributed to the growing research focused on the development of novel oligonucleotide-based drugs and their wide applications in diagnostic procedures.”

The oligonucleotide synthesis market, based on synthesized oligonucelotides (part of product segmentation), is further segmented into primer, probes, DNA Oligos, RNA Oligos, Other synthesized oigonucelotides. Synthesized oligonucelotides have a wide application in research for novel drug development and are mainly used in PCR and sequencing. Additionlly, diagnostic procedures used for detection of genetic disorders, companion diagnostics are also few of the major application areas for synthesized oligonucelotides.

“The primers segment will grow at the highest rate in the synthesized oligos market, by product.”

By Product, synthesized oligonucelotide maket is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos including BNA & LNA oligos. Primers are expected to grow at the highest rate during the forecasted period owing to the extensive use of primers in a wide range of applications such as PCR, sequencing, gene synthesis and cloning. Primers allow aplification of target gene sequences for gene expression studies, molecular diagnostics and genetic analysis.

“By therapeutic application, the neurological disease segment accounted for the largest share of the oligonucleotide synthesis market in 2023.”

The therapeutic application segment is segmented by disease type into neurological, rare and other diseases. In 2023, neurological disease segment accounted for the largest share of this segment as major companies are focusing on the development of oligo-based drugs for the treatment of neurological diseases such as DMD and SMA. Oligo based drugs that are used as therapies for these disorders have most FDA approvals.

“North American region is expected to register a highest CAGR in the oligonucleotide synthesis market.”

The market for oligonucleotide synthesis in North America is estimated to grow at the highest rate during the forecast period. Ongoing investments and funding provided by various government bodies, biotechnology and pharmaceutical companies to develop oligonucelotide based therapies for various rare and neurological disease, presence of strong venture capital ecosystem, growing awareness and early adoption of novel and alternate therapies in this region are few factors that support thr growth of this regional market. North America also has the established pharmceutical manufacturing infrastructure and the presence of the promnient players of the oligonucleotide synthesis market such as Danaher Corporation and Thermo Fisher among other which futher supports the leadership position of this region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side - 30%
• By Designation: Managers- 45%, CXOs, and Director level - 30%, and Executives - 25%
• By Region: North America -35%, Europe - 25%, Asia-Pacific -15%, Latin America -10%, Middle East- 10%, Africa- 5%

List of Companies Profiled in the Report Offering Products For Research and Diagnostic Applications:

• Danaher Corporation (US)
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Eurofins Scientific (Luxembourg)
• LGC Limited (UK)
• Agilent Technologies, Inc. (US)
• Kaneka Corporation (Japan)
• Maravai Lifesciences holdings, Inc. (US)
• Azenta, Inc. (US)
• Twist Bioscience Corporation (US)
• Genscript Biotech Corporation (US)

List of Companies Profiled in the Report Offering Products For Therapeutic Applications:

• Biogen Inc. (US)
• Alnylam Pharmaceuticals, Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Astrazeneca (UK)
• Astellas Pharma Inc. (Japan)
• Jazz Pharmaceuticals Plc (Ireland)
• Nippon Shinyaku, Co. Ltd. (Japan)
• Ionis Pharmaceuticals, Inc. (US)
• Novartis AG (Switzerland)

Note: Above list is inexhaustive

Research Coverage:

This report provides a detailed picture of the oligonucleotide synthesis market. It aims to estimate the market’s size and future growth potential across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oligonucleotide synthesis market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (e.g., Increasing use of synthesized oligos in therapeutic and diagnostic applications, Technological advancements), restraints (e.g., complexities associated with oligonucleotide-based drugs), opportunities (e.g., increasing pharma R&D investments in emerging economies), and challenges (e.g., lack of standard regulations) are influencing the growth of the oligonucleotide synthesis market.
• Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the oligonucleotide synthesis market across varied regions.
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market.
• Pipeline Analysis: Comprehensive information about products under clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), among others offering products for research & diagnostic applications and Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others offering products for therapeutic applications.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION
FIGURE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: REGIONAL SEGMENTATION
  1.4.1 YEARS CONSIDERED
  1.4.2 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
  1.7.1 RECESSION IMPACT: OLIGONUCLEOTIDE SYNTHESIS MARKET

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
FIGURE 3 RESEARCH DESIGN
  2.1.1 SECONDARY DATA
  2.1.2 PRIMARY DATA
FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2023
FIGURE 7 MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2023
FIGURE 8 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH AND DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023
FIGURE 9 ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023
FIGURE 10 MARKET VALIDATION FROM PRIMARY EXPERTS
  2.2.1 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
FIGURE 11 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
2.3 MARKET GROWTH FORECAST
FIGURE 12 CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2024–2029
FIGURE 13 CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET (THERAPEUTIC APPLICATIONS), 2024–2029
FIGURE 14 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET
2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION
2.5 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 15 DATA TRIANGULATION METHODOLOGY
2.6 STUDY ASSUMPTIONS
2.7 RISK ANALYSIS
2.8 IMPACT OF RECESSION ON OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)

3 EXECUTIVE SUMMARY

FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2024-2029 (USD MILLION)
FIGURE 19 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET

4 PREMIUM INSIGHTS

4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
FIGURE 20 INCREASING USE OF SYNTHESIZED OLIGOS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION AND COUNTRY (2023)
FIGURE 21 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY PRODUCT, 2024 VS. 2029
FIGURE 22 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2029
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2023
FIGURE 23 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 24 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 3 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
  5.2.1 DRIVERS
    5.2.1.1 Increasing use of synthesized oligos in therapeutic and diagnostic applications
TABLE 4 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016-2023)
    5.2.1.2 Technological advancements
    5.2.1.3 Growing government investments in life science research and synthetic biology
    5.2.1.4 Growing focus on precision/personalized medicine
  5.2.2 RESTRAINTS
    5.2.2.1 Complexities associated with therapeutic oligonucleotides
  5.2.3 OPPORTUNITIES
    5.2.3.1 Increasing R&D investments by key players in emerging economies
  5.2.4 CHALLENGES
    5.2.4.1 Lack of standard regulations
    5.2.4.2 Delivery of oligonucleotide drugs to specific targets
5.3 MARKET TRENDS
  5.3.1 FOCUS ON DEVELOPING NEW DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
  5.3.2 FOCUS ON DEVELOPING NEW TECHNOLOGIES FOR SUSTAINABLE AND LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
  5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
TABLE 5 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL AND RARE DISEASES
TABLE 6 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE MANUFACTURERS
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 27 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
5.6 VALUE CHAIN ANALYSIS
FIGURE 28 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
5.7 ECOSYSTEM ANALYSIS
FIGURE 29 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET
  5.7.1 ROLE IN ECOSYSTEM
5.8 TECHNOLOGY ANALYSIS
  5.8.1 KEY TECHNOLOGIES
    5.8.1.1 Solid-phase synthesis
    5.8.1.2 Liquid-phase synthesis
    5.8.1.3 Enzymatic oligo synthesis
  5.8.2 COMPLEMENTARY TECHNOLOGIES
    5.8.2.1 Polymerase chain reaction (PCR)
    5.8.2.2 Next-generation sequencing
  5.8.3 ADJACENT TECHNOLOGIES
    5.8.3.1 Clustered regularly interspaced short palindromic repeats (CRISPR)
5.9 PRICING ANALYSIS
TABLE 7 INDICATIVE PRICING OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
TABLE 8 AVERAGE SELLING PRICE FOR MAJOR OLIGONUCLEOTIDE-BASED DRUGS
5.10 PATENT ANALYSIS
  5.10.1 PATENTS FILED, BY DOCUMENT TYPE, 2012–2023
FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012–DECEMBER 2023)
TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
5.11 PIPELINE ANALYSIS
FIGURE 31 NUMBER OF ONGOING CLINICAL TRIALS FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COMPANY
FIGURE 32 NUMBER OF ESTIMATED LAUNCHES, 2024–2028
TABLE 10 OLIGONUCLEOTIDE-BASED DRUGS IN CLINICAL PIPELINE
5.12 TRADE ANALYSIS
5.13 KEY CONFERENCES & EVENTS IN 2024–2025
TABLE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS
5.14 REGULATORY LANDSCAPE
  5.14.1 REGULATORY ANALYSIS
  5.14.2 REGULATORY BODIES
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 PORTER’S FIVE FORCES ANALYSIS
TABLE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
  5.15.1 DEGREE OF COMPETITION
  5.15.2 BARGAINING POWER OF SUPPLIERS
  5.15.3 BARGAINING POWER OF BUYERS
  5.15.4 THREAT OF SUBSTITUTES
  5.15.5 THREAT OF NEW ENTRANTS
5.16 KEY STAKEHOLDERS & BUYING CRITERIA
  5.16.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  5.16.2 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS
5.17 KEY BUYING CRITERIA
  5.17.1 BUYING CRITERIA OF END USERS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS
  5.17.2 BUYING CRITERIA FOR SYNTHESIZED OLIGONUCLEOTIDES, BY END USER
  5.17.3 BUYING CRITERIA OF HOSPITALS FOR OLIGONUCLEOTIDE THERAPEUTIC PRODUCTS
  5.17.4 BUYING CRITERIA FOR OLIGONUCLEOTIDE-BASED THERAPEUTIC PRODUCTS BY HOSPITALS
5.18 CASE STUDY ANALYSIS
  5.18.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
  5.18.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
  5.18.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
5.19 INVESTMENT/FUNDING SCENARIO

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

6.1 INTRODUCTION
TABLE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
6.2 OLIGONUCLEOTIDE-BASED DRUGS
TABLE 19 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 24 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 25 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2022–2029 (NUMBER OF VIALS)
  6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
TABLE 27 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
    6.2.1.1 Antisense oligonucleotide-based drugs
      6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth
TABLE 28 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
TABLE 29 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 30 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 34 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 35 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
    6.2.1.2 siRNA oligonucleotide-based drugs
      6.2.1.2.1 Large pipeline of products to favor market growth
TABLE 36 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
TABLE 37 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 38 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 39 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
    6.2.1.3 Other oligonucleotide-based drugs
TABLE 44 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS
TABLE 45 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 46 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 47 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 51 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 SYNTHESIZED OLIGONUCLEOTIDES
TABLE 52 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 53 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 56 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
    6.3.1.1 Primers
      6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth
TABLE 60 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 61 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 64 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
    6.3.1.2 Probes
      6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth
TABLE 67 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
    6.3.1.3 DNA oligonucleotides
      6.3.1.3.1 Diverse usage of DNA oligos to support market growth
TABLE 74 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 75 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 77 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 79 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 80 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
    6.3.1.4 RNA oligonucleotides
      6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth
TABLE 81 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 87 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
    6.3.1.5 Other synthesized oligonucleotides
TABLE 88 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 89 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 93 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 94 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
TABLE 95 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
    6.3.2.1 Custom oligonucleotides
      6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth
TABLE 96 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 97 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 99 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 100 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
    6.3.2.2 Predesigned oligonucleotides
      6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption
TABLE 103 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 104 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 105 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4 REAGENTS & CONSUMABLES
  6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
TABLE 110 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 111 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 114 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 115 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.5 EQUIPMENT
  6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET
TABLE 117 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

7.1 INTRODUCTION
TABLE 124 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
7.2 THERAPEUTIC APPLICATIONS
TABLE 125 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 126 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 129 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
    7.2.1.1 Neurological disorders
      7.2.1.1.1 Growing research on use of oligonucleotide-based drugs for treatment of DMD and SMA to promote market growth
TABLE 133 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 134 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 135 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 136 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
    7.2.1.2 Rare diseases
      7.2.1.2.1 High specificity and efficacy of oligo-based drugs against rare diseases to support growth
TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
    7.2.1.3 Other diseases
TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 RESEARCH APPLICATIONS
TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 156 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 157 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 159 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 161 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  7.3.1 PCR
    7.3.1.1 Increasing use of PCR in molecular biology research to drive market growth
TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2022–2029 (USD MILLION)
TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION)
  7.3.2 SEQUENCING
    7.3.2.1 Advancements in sequencing technologies and low cost of DNA sequencing to boost growth
TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  7.3.3 OTHER RESEARCH APPLICATIONS
TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 DIAGNOSTIC APPLICATIONS
  7.4.1 INCREASING DEMAND FOR RELIABLE, SPECIFIC, AND FAST METHODS FOR DETECTION OF VARIOUS DISEASES TO SUPPORT GROWTH
TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

8.1 INTRODUCTION
TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
8.2 HOSPITALS
  8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET GROWTH
TABLE 191 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
TABLE 192 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 193 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 194 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 195 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 196 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 197 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO DRIVE GROWTH
TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
8.4 DIAGNOSTIC LABORATORIES
  8.4.1 GROWING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL GROWTH
TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
  8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES PROVIDED BY CROS & CMOS TO FAVOR MARKET GROWTH
TABLE 212 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2022–2029 (USD MILLION)
TABLE 213 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 214 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 215 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 216 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 217 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 218 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
8.6 ACADEMIC RESEARCH INSTITUTES
  8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET GROWTH
TABLE 219 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 220 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 221 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 222 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 223 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 224 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 225 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION

9.1 INTRODUCTION
TABLE 226 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2022–2029 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 33 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
TABLE 227 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 228 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 229 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 230 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 231 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 232 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 233 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 234 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 235 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.2.1 US
    9.2.1.1 Government initiatives and strategic developments by major players to drive market growth
TABLE 236 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 237 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 238 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 239 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 240 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 241 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 242 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 243 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.2.2 CANADA
    9.2.2.1 Strong research infrastructure and availability of funding to support market growth
TABLE 244 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 245 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 246 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 247 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 248 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 249 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 250 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.2.3 NORTH AMERICA: RECESSION IMPACT
9.3 EUROPE
FIGURE 34 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
TABLE 252 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 253 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 254 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 255 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 256 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 257 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 258 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 259 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.3.1 GERMANY
    9.3.1.1 Government and private funding towards health research to support market growth
TABLE 261 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 262 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 264 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 265 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 266 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 267 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 268 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.3.2 UK
    9.3.2.1 Strategic collaborations and partnerships between key market players to favor market growth
TABLE 269 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 270 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 271 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 272 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 273 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 274 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 275 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 276 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.3.3 FRANCE
    9.3.3.1 Government initiatives to strengthen R&D activities and growing awareness to propel market growth
TABLE 277 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 278 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 279 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 280 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 282 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 283 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 284 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.3.4 ITALY
    9.3.4.1 Increasing research spending and presence of major pharmaceutical and biotechnology companies to drive market
TABLE 285 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 286 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 287 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 288 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 289 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 290 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 291 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.3.5 SPAIN
    9.3.5.1 Research and expansion initiatives to propel market growth
TABLE 293 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 294 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 295 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 296 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 298 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 299 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 300 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.3.6 REST OF EUROPE
TABLE 301 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 302 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 303 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 304 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 305 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 306 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 307 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 308 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.3.7 EUROPE: RECESSION IMPACT
9.4 ASIA PACIFIC
TABLE 309 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 310 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 311 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 312 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 313 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 314 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 315 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 316 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 317 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.4.1 CHINA
    9.4.1.1 Expansion of major biotechnology and pharmaceutical companies in China to boost market
TABLE 318 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 319 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 320 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 321 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 322 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 323 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 324 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 325 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.4.2 JAPAN
    9.4.2.1 Growing research initiatives and strategic developments to drive market growth in Japan
TABLE 326 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 327 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 328 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 329 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 330 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 331 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 332 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 333 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.4.3 INDIA
    9.4.3.1 Strong initiatives to develop bioclusters and increasing adoption of genomic technologies to aid market growth
TABLE 334 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 335 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 336 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 337 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 338 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 339 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 340 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 341 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.4.4 AUSTRALIA
    9.4.4.1 Increasing government initiatives and research funding to support market growth
TABLE 342 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 343 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 344 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 345 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 346 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 347 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 348 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 349 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.4.5 SOUTH KOREA
    9.4.5.1 Growing research activities and strategic expansions in field of oligonucleotide synthesis to propel market growth
TABLE 350 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 351 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 352 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 353 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 354 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 355 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 356 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 357 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.4.6 REST OF ASIA PACIFIC
TABLE 358 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 359 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 360 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 361 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 362 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 363 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 364 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 365 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.4.7 ASIA PACIFIC: RECESSION IMPACT
9.5 LATIN AMERICA
TABLE 366 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 367 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 368 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 369 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 370 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 371 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 372 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 373 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 374 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.5.1 BRAZIL
    9.5.1.1 Availability of major oligo-based therapies to support market growth
TABLE 375 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 376 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 377 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 378 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 379 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 380 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 381 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 382 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.5.2 MEXICO
    9.5.2.1 Growing adoption of NGS technology and increasing research and awareness towards oligonucleotide-based therapies to support growth
TABLE 383 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 384 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 385 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 386 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 387 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 388 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 389 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 390 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.5.3 ARGENTINA
    9.5.3.1 Increase in research collaborations and government support to boost market growth
TABLE 391 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 392 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 393 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 394 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 395 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 396 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 397 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 398 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.5.4 REST OF LATIN AMERICA
TABLE 399 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 400 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 401 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 402 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 403 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 404 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 405 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 406 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.5.5 LATIN AMERICA: RECESSION IMPACT
9.6 MIDDLE EAST
TABLE 407 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 408 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 409 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 410 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 411 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 412 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 413 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 414 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 415 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.6.1 GCC COUNTRIES
TABLE 416 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 417 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 418 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 419 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 420 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 421 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 422 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 423 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 424 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
    9.6.1.1 Saudi Arabia (KSA)
      9.6.1.1.1 Increasing focus on research and government support to propel market growth
TABLE 425 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 426 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 427 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 428 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 429 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 430 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 431 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 432 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
    9.6.1.2 United Arab Emirates (UAE)
      9.6.1.2.1 Government-driven initiatives and investments to boost market growth
TABLE 433 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 434 UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 435 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 436 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 437 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 438 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 439 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 440 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
    9.6.1.3 Rest of GCC Countries
TABLE 441 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 442 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 443 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 444 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 445 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 446 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 447 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 448 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.6.2 REST OF MIDDLE EAST
TABLE 449 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 450 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 451 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 452 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 453 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 454 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 455 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 456 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.6.3 MIDDLE EAST: RECESSION IMPACT
9.7 AFRICA
  9.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
TABLE 457 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 458 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 459 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 460 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 461 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 462 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION)
TABLE 463 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 464 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION)
  9.7.2 AFRICA: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  10.2.1 KEY PLAYERS STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2021–2024
  10.2.2 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS), 2021–2024
10.3 REVENUE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2021–2023
10.4 MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS), BY KEY PLAYER, 2023
TABLE 465 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): DEGREE OF COMPETITION
10.5 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS)
FIGURE 37 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2021–2023
FIGURE 38 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS), BY KEY PLAYER, 2023
TABLE 466 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): DEGREE OF COMPETITION
10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2023
  10.6.1 STARS
  10.6.2 EMERGING LEADERS
  10.6.3 PERVASIVE PLAYERS
  10.6.4 PARTICIPANTS
FIGURE 39 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2023
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2023
  10.7.1 STARS
  10.7.2 EMERGING LEADERS
  10.7.3 PERVASIVE PLAYERS
  10.7.4 PARTICIPANTS
FIGURE 40 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2023
  10.7.5 COMPANY FOOTPRINT ANALYSIS
FIGURE 41 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): COMPANY FOOTPRINT
TABLE 467 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): PRODUCT FOOTPRINT
TABLE 468 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): APPLICATION FOOTPRINT
TABLE 469 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): REGIONAL FOOTPRINT
FIGURE 42 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): COMPANY FOOTPRINT
TABLE 470 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): REGIONAL FOOTPRINT
TABLE 471 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): PRODUCT FOOTPRINT
TABLE 472 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): APPLICATION FOOTPRINT
10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  10.8.1 PROGRESSIVE COMPANIES
  10.8.2 RESPONSIVE COMPANIES
  10.8.3 DYNAMIC COMPANIES
  10.8.4 STARTING BLOCKS
FIGURE 43 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2023
  10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 473 DETAILED LIST OF KEY STARTUPS/SMES
TABLE 474 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
10.9 COMPETITIVE SCENARIO
  10.9.1 PRODUCT APPROVALS
TABLE 475 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS, JANUARY 2021–FEBRUARY 2024
TABLE 476 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2021-FEBRUARY 2024
TABLE 477 OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2021-FEBRUARY 2024
10.10 VALUATION AND FINANCIAL METRICS OF OLIGONUCLEOTIDE SYNTHESIS MARKET VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
FIGURE 44 EV/EBITDA OF KEY VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
10.11 VALUATION AND FINANCIAL METRICS OF OLIGONUCLEOTIDE SYNTHESIS MARKET VENDORS (THERAPEUTIC APPLICATIONS)
FIGURE 46 EV/EBITDA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
10.12 BRAND/PRODUCT COMPARATIVE ANALYSIS
  10.12.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH AND DIAGNOSTIC APPLICATIONS)
  10.12.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)

11 COMPANY PROFILES

(Business overview, Products offered, Recent Developments, MNM view)*
11.1 KEY PLAYERS
  11.1.1 DANAHER CORPORATION
TABLE 478 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 479 DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 480 DANAHER CORPORATION: DEALS
TABLE 481 DANAHER CORPORATION: EXPANSIONS
TABLE 482 DANAHER CORPORATION: OTHER DEVELOPMENTS
  11.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 483 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 49 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 484 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 485 THERMO FISHER SCIENTIFIC INC.: DEALS
  11.1.3 MERCK KGAA
TABLE 486 MERCK KGAA: COMPANY OVERVIEW
FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT (2023)
TABLE 487 MERCK KGAA: PRODUCTS OFFERED
TABLE 488 MERCK KGAA: EXPANSIONS
  11.1.4 LGC LIMITED
TABLE 489 LGC LIMITED: COMPANY OVERVIEW
FIGURE 51 LGC LIMITED: COMPANY SNAPSHOT (2023)
TABLE 490 LGC LIMITED: PRODUCTS OFFERED
TABLE 491 LGC LIMITED: DEALS
TABLE 492 LGC LIMITED: EXPANSIONS
  11.1.5 EUROFINS SCIENTIFIC
TABLE 493 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 52 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)
TABLE 494 EUROFINS SCIENTIFIC: PRODUCTS OFFERED
TABLE 495 EUROFINS SCIENTIFIC: DEALS
  11.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 496 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 497 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 498 AGILENT TECHNOLOGIES, INC.: EXPANSIONS
  11.1.7 KANEKA CORPORATION
TABLE 499 KANEKA CORPORATION: COMPANY OVERVIEW
FIGURE 54 KANEKA CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 500 KANEKA CORPORATION: PRODUCTS OFFERED
TABLE 501 KANEKA CORPORATION: EXPANSIONS
  11.1.8 MARAVAI LIFESCIENCES HOLDINGS, INC.
TABLE 502 MARAVAI LIFESCIENCES HOLDINGS, INC.: COMPANY OVERVIEW
FIGURE 55 MARAVAI LIFESCIENCES HOLDINGS, INC.: COMPANY SNAPSHOT (2023)
TABLE 503 MARAVAI LIFESCIENCES HOLDINGS, INC.: PRODUCTS OFFERED
TABLE 504 MARAVAI LIFESCIENCES HOLDINGS, INC.: DEALS
  11.1.9 AZENTA, INC.
TABLE 505 AZENTA, INC.: COMPANY OVERVIEW
FIGURE 56 AZENTA, INC.: COMPANY SNAPSHOT (2023)
TABLE 506 AZENTA, INC.: PRODUCTS OFFERED
  11.1.10 TWIST BIOSCIENCE CORPORATION
TABLE 507 TWIST BIOSCIENCE CORPORATION: COMPANY OVERVIEW
FIGURE 57 TWIST BIOSCIENCE CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 508 TWIST BIOSCIENCE CORPORATION: PRODUCTS OFFERED
TABLE 509 TWIST BIOSCIENCE CORPORATION: DEALS
  11.1.11 GENSCRIPT BIOTECH CORPORATION
TABLE 510 GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW
FIGURE 58 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 511 GENSCRIPT BIOTECH CORPORATION: PRODUCTS OFFERED
TABLE 512 GENSCRIPT BIOTECH CORPORATION: EXPANSIONS
11.2 KEY PLAYERS (THERAPEUTIC PRODUCTS)
  11.2.1 BIOGEN INC.
TABLE 513 BIOGEN INC.: COMPANY OVERVIEW
FIGURE 59 BIOGEN INC.: COMPANY SNAPSHOT (2023)
TABLE 514 BIOGEN INC.: PRODUCTS OFFERED
TABLE 515 BIOGEN INC.: PRODUCT APPROVALS
TABLE 516 BIOGEN INC.: DEALS
TABLE 517 BIOGEN INC.: EXPANSIONS
  11.2.2 ALNYLAM PHARMACEUTICALS, INC.
TABLE 518 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 60 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
TABLE 519 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
TABLE 520 ALNYLAM PHARMACEUTICALS INC.: PRODUCT APPROVALS
TABLE 521 ALNYLAM PHARMACEUTICALS INC.: DEALS
  11.2.3 SAREPTA THERAPEUTICS, INC.
TABLE 522 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
FIGURE 61 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2023)
TABLE 523 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 524 SAREPTA THERAPEUTICS: PRODUCT APPROVALS
TABLE 525 SAREPTA THERAPEUTICS: DEALS
TABLE 526 SAREPTA THERAPEUTICS: EXPANSIONS
  11.2.4 ASTRAZENECA
TABLE 527 ASTRAZENECA: COMPANY OVERVIEW
FIGURE 62 ASTRAZENECA: COMPANY SNAPSHOT (2023)
TABLE 528 ASTRAZENECA: PRODUCTS OFFERED
TABLE 529 ASTRAZENECA: DEALS
TABLE 530 ASTRAZENECA: PRODUCT APPROVALS
  11.2.5 ASTELLAS PHARMA INC.
TABLE 531 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
FIGURE 63 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2022)
TABLE 532 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
TABLE 533 ASTELLAS PHARMA INC.: DEALS
TABLE 534 ASTELLAS PHARMA INC.: PRODUCT APPROVALS
  11.2.6 JAZZ PHARMACEUTICALS PLC
TABLE 535 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
FIGURE 64 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2023)
TABLE 536 JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED
  11.2.7 NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.)
TABLE 537 NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW
FIGURE 65 NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2022)
TABLE 538 NIPPON SHINYAKU, CO. LTD.: PRODUCTS OFFERED
  11.2.8 IONIS PHARMACEUTICALS, INC.
TABLE 539 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
FIGURE 66 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
TABLE 540 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED
TABLE 541 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS
TABLE 542 IONIS PHARMACEUTICALS, INC.: DEALS
  11.2.9 NOVARTIS AG
TABLE 543 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 67 NOVARTIS AG: COMPANY SNAPSHOT (2023)
TABLE 544 NOVARTIS AG: PRODUCTS OFFERED
TABLE 545 NOVARTIS AG: PRODUCT APPROVALS
TABLE 546 NOVARTIS AG: DEALS
11.3 OTHER PLAYERS
  11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
  11.3.2 BIOLEGIO BV
  11.3.3 BIOLYTIC LAB PERFORMANCE, INC.
  11.3.4 BIOCOMMA LIMITED
  11.3.5 REVVITY, INC. (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.)
  11.3.6 BIO-SYNTHESIS, INC.
  11.3.7 CREATIVE BIOGENE
  11.3.8 REPROCELL, INC. (THROUGH SUBSIDIARY BIOSERVE)
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX

12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 RELATED REPORTS
12.4 AUTHOR DETAILS

About

In the coming five years, growth in the oligonucleotide synthesis market is likely to be centered on China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos along with an increase in the R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players in the APAC market is another factor driving the growth of this market. For instance, in July 2013, Integrated DNA Technologies, Inc. (IDT) opened an oligonucleotides manufacturing facility in Singapore to cater to the research companies in the APAC region, thereby establishing its footprint in the APAC market. Such developments are likely to spur the growth of the APAC oligonucleotide synthesis market in the coming years.

The key strategies followed by most companies in the oligonucleotide synthesis market are new product launches; agreements, collaborations, and partnerships; mergers and acquisitions; and expansions. Of all the growth strategies adopted by players in this field, agreements, collaborations, and partnerships accounted for the largest share of XX% of the overall growth strategies from 2010 to 2014. Some leading players adopting these strategies are BioAutomation Corporation (U.S.), Eurofins Genomics (Germany), and GE Healthcare (U.K.). Expansions accounted for the second-largest share of XX% of the overall growth strategies adopted by the players in the market.

The prominent players in the oligonucleotide synthesis market are Agilent Technologies, Inc. (U.S.), BioAutomation Corporation (U.S.), BioSearch Technologies, Inc. (U.S.), Eurofins Genomics (Germany), Eurogentec (Belgium), GE Healthcare (U.K.), Glen Research (U.S.), Gene Link, Inc. (U.S.), GenScript USA Inc. (U.S.), GeneDesign, Inc. (Japan), Integrated DNA Technologies, Inc. (IDT) (U.S.), Link Technologies, Ltd. (U.K.), Nitto Denko Avecia, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and TriLink BioTechnologies, Inc. (U.S.).

North America commands the largest share of the global oligonucleotide synthesis market, followed by Europe. However, the European oligonucleotide synthesis market is expected to grow at a slower pace as compared to North America due to the Eurozone debt crisis. The Asia-Pacific market, on the other hand, is in the growth phase and is the fastest-growing region in the global oligonucleotide synthesis market. The growth in the APAC oligonucleotide synthesis market is likely to be centered at China, Malaysia, Singapore, and India. This can be attributed to the growing availability of synthesized oligos and the increase in R&D funding and activities in the APAC region. Furthermore, increasing focus of prominent players on the APAC region is another factor driving the growth of this market.

Oligonucleotide synthesis is a highly commoditized market. With its rising attractiveness, an increasing number of companies are moving into this niche market, resulting in price pressure. Oligos have been branded as relatively more expensive research tools as compared to other life sciences research tools. This is further restricting the industry growth, as there are certain limitations related to increasing the cost of oligos. This factor is making it difficult for market players to survive and/or grow at a faster and desired pace. However, market consolidation in the coming years can bring price enhancement in this industry.

The importance of synthetic oligonucleotides as therapeutic drugs for treating diseases has grown significantly over the last decade. Some of the major driving factors for this growth are characterization of more targets following the identification of the human genome, advancements in antisense oligonucleotides, and the development of double stranded small interfering RNA (siRNA). Therapeutic oligos can either be single stranded such as antisense oligonucleotides or double stranded such as siRNA. Furthermore, therapeutic oligos can be useful in treating diseases ranging from viral infections, respiratory diseases, and cancer to rare diseases such as Duchenne Muscular Dystrophy (DMD), Cystic Fibrosis, and Thrombic Thrombocytopenic Purpura.

Currently, only two oligonucleotide-based drugs, namely, Vitravene and Macugen have received market approval and a large number of oligonucleotide-based drugs are in various stages of clinical development in the U.S., Canada, Europe, and other parts of the world. As of 2011, there were over XX oligonucleotide-based drugs in clinical development in the U.S., Europe, and Canada; some of these include antisense oligonucleotides, immunostimulatory oligonucleotides, DNA duplex decoys, siRNAs, ribozymes, microRNAs, aptamers, and spiegelmers. Although most oligonucleotides in clinical development are chemically similar, the mechanisms of their action vary widely. As a result, the development of a unified set of regulatory guidelines that can effectively address the safety and quality requirements for such a diverse group of molecular entities with various unique mechanisms of action is a challenging task.

There are no formal regulatory guidelines available from any regulatory agency for the development of this class of therapeutics. It has been a general practice for regulatory agencies to apply guidelines proposed for small molecules to oligonucleotide therapeutics, owing to their similar characteristics. These include all quality-related regulatory guidelines issued by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Thus, there is a need to address the basic regulatory issues regarding the chemistry, manufacturing, and control of drugs and products belonging to this unique class of therapeutics.